Abstract
The intestine is a unique immune environment that must respond to infectious organisms but remain tolerant to commensal microbes and food antigens. However, the molecular mechanisms that regulate immune cell function in the intestine remain unclear. Here we identify the POK/ZBTB family transcription factor hypermethylated in cancer 1 (HIC1, ZBTB29) as a central component of immunity and inflammation in the intestine. HIC1 is specifically expressed in immune cells in the intestinal lamina propria (LP) in the steady state and mice with a T-cell-specific deletion of HIC1 have reduced numbers of T cells in the LP. HIC1 expression is regulated by the Vitamin A metabolite retinoic acid, as mice raised on a Vitamin A-deficient diet lack HIC1-positive cells in the intestine. HIC1-deficient T cells overproduce IL-17A in vitro and in vivo, and fail to induce intestinal inflammation, identifying a critical role for HIC1 in the regulation of T-cell function in the intestinal microenvironment under both homeostatic and inflammatory conditions.
Similar content being viewed by others
Introduction
The intestinal immune system is constantly interacting with non-pathogenic commensal organisms and innocuous food antigens that must be tolerated immunologically, while simultaneously maintaining the ability to rapidly respond to infectious organisms and toxins. To maintain this balance, unique immune cell populations are found in the intestinal microenvironment. For example, intestinal-resident dendritic cells that express the surface marker CD103 have been shown to affect intestinal homeostasis by producing the vitamin A metabolite retinoic acid (RA).1 Intestinal macrophages have also been shown to have a central role in tolerance in the intestine.2, 3 Specific subsets of CD4+ T helper (TH) cells, primarily FOXP3-expressing regulatory T cells (Treg cells) and IL-17A-producing TH cells (TH17 cells) are enriched in the intestinal lamina propria (LP),4 whereas CD8+ T cells and γδ T cells are found in the intraepithelial compartment,5 acting in conjunction with IgA-producing B cells that are required to maintain tolerance to the commensal flora.6 However, the molecular mechanisms that regulate intestinal immune cell function in health and disease are not fully defined.
The POZ and Kruppel/Zinc Finger and BTB (POK/ZBTB) proteins are a family of transcription factors that have critical roles in a variety of biological processes such as gastrulation, limb formation, cell cycle progression, and gamete formation.7 In the immune system, POK/ZBTB proteins are key regulators in cellular differentiation and function.8 For example, B-cell CLL/Lymphoma 6 (BCL6, ZBTB27) is critical for the development of germinal centers following immunization or infection. BCL6 is expressed at high levels in germinal center B cells9 and T follicular helper cells10 that together control the germinal center response. Promyelocytic leukemia zinc finger (ZBTB16) is required for natural killer T-cell development11 and expression of promyelocytic leukemia zinc finger has recently been shown to identify a multipotent progenitor of innate lymphoid cells.12 TH-inducing POZ/Kruppel-Like factor (ThPOK, ZBTB7B) is a master regulator of TH-cell development in the thymus.13, 14 Hypermethylated in cancer 1 (HIC1, ZBTB29) is a member of this family and has been shown to regulate proliferation and p53-dependent survival in a wide range of tumors. HIC1 is epigenetically silenced through DNA methylation in various human cancers15, 16 and it has been proposed that HIC1-dependent repression of SIRT1 was critical for the function of p53.17 However, the role of HIC1 in immune cells has not been examined.
In this study, we identify HIC1 as a regulator of intestinal immune responses under homeostatic and inflammatory conditions. We demonstrate that HIC1 is expressed in immune cells specifically in the intestinal LP but not in other lymphoid or non-lymphoid tissues in the steady state. In the absence of HIC1 in T cells, we observe a significant reduction in the frequency of T cells in the LP and intraepithelial compartment, coincident with increased TH17-cell responses. HIC1 expression in the LP is regulated by the vitamin A metabolite RA and under inflammatory conditions in the intestine, loss of HIC1 specifically in T cells renders mice resistant to the development of intestinal inflammation, suggesting that HIC1 is required for the pathogenicity of T cells in vivo. Thus, HIC1 has a central role in intestinal immune homeostasis and inflammation.
Results
HIC1 expression in immune cells is restricted to the intestine
To begin to address the role of HIC1 in the immune system, we examined the expression of HIC1 in CD45+ leukocytes in various tissues of mice with a fluorescent reporter gene inserted in the Hic1 locus (Hic1Citrine mice).18 Citrine expression in CD45+ cells was restricted to the intestine, with the only detectable Citrine-positive cells in the LP and intraepithelial space (Figure 1a). Further characterization of the leukocytes in the LP revealed that a majority of T-cell receptor β (TCRβ) chain-expressing CD4+ and CD8+ T cells and TCRγδ+ CD8+ T cells in the LP-expressed HIC1 (Figure 1b) and that TCRβ+ CD8+ and TCRγδ+ CD8+ intraepithelial lymphocytes also expressed HIC1 (Figure 1c). We also found that most MHCII+ CD11c+ CD64- dendritic cells and MHCII+ CD64+ F4/80+ macrophages expressed HIC1 (Supplementary Figure 1 online). However, HIC1 expression was not generalized for all lymphocytes in the LP, as B220+ B cells did not express HIC1 (Figure 1b). Thus, HIC1 expression in immune cells specifically identifies intestinal resident populations.
T cell-intrinsic expression of HIC1 regulates intestinal immune homeostasis
As HIC1 was expressed in multiple immune cell populations in the LP, we next sought to determine the cell-intrinsic functions of HIC1 by focusing on its role specifically in T cells. To do this, we crossed mice with loxP sites flanking the Hic1 gene (Hic1fl/fl mice) with mice that express the Cre recombinase under control of the Cd4 enhancer and promoter (Cd4-Cre mice) to generate mice with a T cell-intrinsic deletion of Hic1 (Hic1ΔT mice). Hic1ΔT mice displayed normal thymic development (Supplementary Figure 2a and b) and had normal frequencies of CD4+ and CD8+ T cells in the spleen (Supplementary Figure 2c) or mesenteric lymph nodes (Supplementary Figure 2d). HIC1 also had no effect on the activation state of splenic CD4+ T cells, as we observed equivalent expression of CD62L and CD44 between Hic1f/f and Hic1ΔT mice (Supplementary Figure 2e). Finally, HIC1 was not required for the development of FOXP3+ CD25+ CD4+ T cells in the spleen or mLNs (Supplementary Figure 2f). Thus, HIC1 expression is dispensable for peripheral T-cell homeostasis. However, we found that the frequency and number of CD4+ and CD8+ TCRβ+ cells in the LP (Figures 2a and b) and CD8+ T cells in the intraepithelial compartment (Figures 2a and b) were significantly reduced in the absence of HIC1, demonstrating that T cell-intrinsic expression of HIC1 is required for intestinal T-cell homeostasis.
Lamina propria lymphocytes (LPLs) and intraepithelial lymphocytes display an activated, memory phenotype that includes the markers CD69 and CD103, cell surface molecules that are important for retention in the intestinal microenvironment. CD69 has been shown to negatively regulate expression of sphingosine-1-phosphate receptor, which must be downregulated to establish tissue-residency,19, 20 whereas CD103 binds to the epithelial cell-expressed E-cadherin and is required for maintenance of intestinal T cells.21 We found that HIC1-deficient CD4+ and CD8+ T cells in the LP and intraepithelial compartments expressed significantly reduced levels of CD69 and CD103 (Figures 2c and d). Strikingly, there was an almost complete loss of CD103+ CD69+ CD4+ T cells in the LP (Figures 2c and d). Thus, the reduced frequency and number of CD4+ and CD8+ LPLs and intraepithelial lymphocytes in Hic1ΔT mice is associated with reduced expression of CD69 and CD103.
HIC1 is a negative regulator of IL-17A production by CD4+ T cells
In the intestinal LP, CD4+ TH17 and Treg cells are found at higher frequencies than other TH-cell subsets. Analysis of the CD4+ LPLs showed that although frequency of FOXP3+ Treg cells were equivalent between Hic1fl/fl and Hic1ΔT mice, the frequency of RORγt+ IL-17A-expressing TH17 cells in Hic1ΔT mice was significantly increased (Figures 3a and b). Further, splenic T cells in Hic1ΔTmice displayed a small but significant increase in the frequency of IL-17A expression TH17 cells (Supplementary Figure 3). These results suggest that in addition to regulating T-cell numbers in the intestine, HIC1 deficiency in T cells had a specific effect on TH17-cell differentiation. To directly examine the role of HIC1 in TH-cell differentiation, we stimulated TH cells that were purified from the spleen and peripheral lymph nodes of naive Hic1fl/fl and Hic1ΔT mice (Figure 3c) under diverse polarizing conditions. HIC1 deficiency had no effect on the development of TH1, TH2, or tumor growth factor (TGF)-β-induced Treg cells (Supplementary Figure 4). Consistent with our in vivo results, we observed a significant increase in the production of IL-17A by HIC1-deficient TH cells activated under TH17 cell-promoting conditions, with heightened frequency and mean fluorescence intensity of IL-17A+ cells (Figure 3d), resulting in a significant increase in the levels of secreted IL-17A (Figure 3e), which was also associated with increased Il17a expression in HIC1-deficient TH17 cells (Figure 3f). Retroviral transduction of HIC1 into differentiating TH17 cells resulted in a complete inhibition of IL-17A production (Figures 3g and h). Taken together, these results suggest that HIC1 is a cell-intrinsic negative regulator of IL-17A production during TH17-cell differentiation.
RA regulates expression of HIC1 in T cells in vitro and in vivo
The vitamin A metabolite RA has a critical role in intestinal immune homeostasis.22 Previous studies have shown that mice raised on a diet lacking vitamin A (VAD diet) have defects in TH-cell activation and intestinal migration, resulting in an overall impairment in T-cell-driven immune responses in the intestine.23, 24, 25 To test whether RA influenced HIC1 expression in intestinal TH cells, we raised Hic1Citrine mice on a VAD diet. We found that LP TH cells from VAD mice failed to express HIC1 (Figure 4a), suggesting that HIC1 expression in TH cells in the LP is dependent on the presence of RA. Consistent with this, addition of RA to TH cellsisolated from spleen or lymph nodes of mice activated in vitro with antibodies against CD3 and CD28 resulted in an upregulation of HIC1 at the mRNA and protein levels (Figures 4b and c). Analysis of HIC1 expression using Hic1Citrine mice further demonstrated that treatment of activated TH with RA led to increased HIC1 expression (Figure 4d). Expression of HIC1 was dependent upon TH-cell activation, as addition of RA to TH cells in the absence of TCR stimulation had no effect on the expression of Hic1 mRNA (Figure 4e). Thus, these results identify HIC1 as an RA-responsive gene in activated TH cells.
HIC1 is dispensable for expression of intestinal homing receptors
RA is critical for migration of immune cells to the intestine24 through the upregulation of intestinal homing molecules, including α4β7 integrin and CCR9.25 Our results showing that Hic1ΔT mice had reduced numbers of intestinal T cells could be owing to reduced expression of intestinal homing molecules, resulting in impaired intestinal migration. However, we failed to observe any reduction in expression of α4β7 and CCR9 on TH cells in the presence or absence of HIC1 following activation in the presence of RA (Figure 5a). Further, we found that TH cells isolated from the Peyer’s patches or mLNs of Hic1ΔT mice were not deficient in expression of CCR9 (Supplementary Figure 5). These results demonstrate that other HIC1-dependent mechanisms such as reduced expression of CD69 and CD103 were responsible for the paucity of TH cells in the LP and that HIC1 is dispensable for RA-dependent induction of intestinal homing molecules.
HIC1 is not required for inhibitory effects of RA on TH17-cell differentiation
Several studies have demonstrated that RA can negatively affect the differentiation of TH17 cells26, 27, 28, 29 although the precise mechanisms remain unclear. Based on our data showing heightened IL-17A production by HIC1-deficeint TH17 cells in vitro and in vivo, we hypothesized that expression of HIC1 would be required for the RA-dependent reduction in TH17-cell differentiation. In contrast to our expectations, addition of RA to either HIC1-sufficient or -deficient TH cells led to a significant reduction in the expression of IL-17A (Figure 5b). Thus, although HIC1 is upregulated by RA in TH cells and HIC1-deficient TH17 cells express increased levels of IL-17A in vitro and in vivo, HIC1 is dispensable for RA-dependent regulation of TH17 cell responses in vitro.
HIC1 regulates T cell-mediated inflammation in the intestine
We next examined whether dysregulated TH-cell responses observed in naive Hic1ΔT mice had any effect on the development of intestinal inflammation. Despite the reduced numbers of TH cells in the LP of Hic1ΔT mice and the dysregulated production of IL-17A by HIC1-deficient TH17 cells, we failed to observe any significant differences in intestinal architecture between naive Hic1fl/fl or Hic1ΔT mice (Figure 6a, left panels). After induction of intestinal inflammation with intraperitoneal injection of a monoclonal antibody against CD3,30, 31, 32 Hic1ΔT mice displayed less intestinal inflammation compared with control Hic1fl/fl mice (Figures 6a and b). Although we observed fewer CD4+ T cells in the intestine of treated Hic1ΔT mice (Figure 6c), we did observe an increase in the number of CD4+ T cells in the LP of treated Hic1ΔT mice compared with naive Hic1ΔT mice (Figures 2a and b), further demonstrating that intestinal migration is not completely impaired in the absence of HIC1. Analysis of cytokine production by TH cells from the LP and mLN of anti-CD3-treated mice identified an increased frequency of IL-17A-producing TH cells without any changes in the frequency of IFN-γ-producing cells (Figures 6c and d), similar to our results under steady-state conditions. Thus, T cell-intrinsic expression of HIC1 modulates inflammation in the intestine, potentially by negatively regulating IL-17A production.
To directly assess the cell-intrinsic role of HIC1 in intestinal inflammation, we employed a T-cell transfer model of intestinal inflammation.33 We adoptively transferred naive CD4+ CD25– CD45RBhigh T cells isolated from either Hic1fl/fl or Hic1ΔT mice into Rag1–/– mice. Rag1–/– mice that received control T cells from Hic1fl/fl mice began losing weight ∼4 weeks post transfer (Figure 7a) and showed significant intestinal inflammation by 6 weeks post transfer (Figure 7b). Strikingly, we found that Rag1–/– mice that received T cells from Hic1ΔT mice continued to gain weight and did not develop severe intestinal inflammation (Figures 7a–c). Associated with the reduced disease, there were significantly fewer CD4+ T cells in the intestinal LP (Figure 7d). Furthermore, consistent with our results under homeostatic conditions as well as following α-CD3 treatment, we found that the absence of HIC1 in T cells resulted in heightened production of IL-17A in the LP and spleen with no significant effect on the frequency of IFN-γ-positive cells (Figures 7e and f). Thus, HIC1 expression in T cells is critically required for the development of intestinal inflammation, possibly by limiting expression of IL-17A.
Finally, to determine whether HIC1-deficient T cells have a protective role in a non-T-cell driven model of intestinal inflammation, we employed dextran sodium sulfate (DSS)-induced colitis. This model involves chemically induced epithelial cell damage, which leads to bacterial translocation and activation of sub-epithelial innate immune cells and therefore does not require T or B cells for development of disease.34, 35 Hic1fl/fl mice and Hic1ΔT mice were exposed to 3.5% DSS in their drinking water for 7 days before returning to regular drinking water for one final day. DSS-treated Hic1ΔT mice exhibited attenuated weight loss in comparison with treated Hic1fl/fl mice (Supplementary Figure 6a). At day 8 after DSS treatment, sections from the colon of DSS-treated Hic1ΔT mice revealed negligible damage to the epithelium and a minimal presence of inflammatory cells. In contrast, tissue sections from DSS-treated Hic1fl/fl mice exhibited severe mucosal inflammatory cell infiltrate, sloughing of epithelial cells, and complete loss of crypt architecture (Supplementary Figure 6b and c). Therefore, HIC1-deficient T cells offer a protective function in the development of innate immune cell driven intestinal inflammation.
HIC1 is required to limit STAT3 signaling in TH17 cells
In addition to directly repressing target genes, HIC1 has been shown to negatively regulate gene expression by several mechanisms including the recruitment of co-repressors such as the CtBP, NuRD, and polycomb repressive complex 2 complexes to target genes to mediate gene repression.36, 37 Further, HIC1 has also been shown to indirectly repress transcription by binding to transcriptional activators and preventing binding to target genes. HIC1 has been shown to interact with and inhibit DNA binding of transcription factors such as T-cell factor-4, β-catenin, and STAT3.38, 39, 40 As HIC1-deficient TH17 cells produce heightened levels of the STAT3 target gene IL-17A,41 we hypothesized that increased STAT3 activity was associated with HIC1 deficiency. We first examined the levels of IL-6-induced active phosphorylated STAT3 in HIC1-sufficient and -deficient TH17 cells by flow cytometry. We found that loss of HIC1 had no effect on the frequency of phosphorylated STAT3-positive TH cells (Figure 8a), suggesting that HIC1 did not affect upstream STAT3 activation. However, co-immunoprecipitation studies in TH17 cells of either native HIC1 (Figure 8b) or retrovirally transduced FLAG-tagged HIC1 (Figure 8c) demonstrated that HIC1 and STAT3 interacted in TH17 cells. Thus, our results suggest that HIC1 limits TH17-cell differentiation by binding to STAT3, inhibiting its DNA binding and transcriptional activation. Consistent with this hypothesis, we found increased STAT3 binding to the Il17a promoter in the absence of HIC1 (Figure 8d), whereas there was no difference in binding at an irrelevant site (Il5 promoter). Examination of mRNA expression for other known STAT3 target genes associated with TH17-cell differentiation41 revealed slight but insignificant increases in gene expression of Rorc, Socs3, Irf4, Ahr, or Il23r (Figure 8e). Thus, HIC1 does not appear to directly regulate the molecular machinery that controls TH17-cell differentiation. Instead, our results identify an important role for HIC1 in limiting expression of IL-17A in TH17 cells by inhibition of STAT3 DNA binding.
Discussion
We have identified the transcriptional factor HIC1 as a novel regulator of intestinal immune homeostasis. In the steady state, HIC1 is specifically expressed in immune cells of the intestinal LP and intraepithelial niches in an RA-dependent manner, and mice with a T cell-intrinsic deletion of HIC1 have a marked decrease in the number of T cells in intestinal tissues. HIC1 deficiency leads to increased expression of IL-17A, possibly through the loss of STAT3 inhibition. Under inflammatory conditions, HIC1 expression in T cells is required for intestinal pathology, identifying HIC1 as a potential therapeutic target to treat intestinal inflammation.
Our results suggest that the micronutrient RA regulates HIC1 expression in immune cells in the intestine. In support of this, two unrelated genome-wide expression screens for genes in TH cells regulated by RA signaling have identified HIC1 as an RA/RARα-dependent gene, although no functional analyses were carried out.22, 42 These results are consistent with an in silico study showing that the Hic1 gene contains multiple RA receptor response elements.43 However, HIC1 is dispensable for RA-mediated expression of intestinal homing molecules and RA-dependent suppression of IL-17A production in vitro, suggesting that the RA-HIC1 axis has a specific role in regulating intestinal T-cell homeostasis that remains to be defined.
T cell-intrinsic deletion of HIC1 resulted in a significant reduction in the frequency and number of T cells in the intestinal microenvironment. Interestingly, mice raised on a VAD diet also display reduced numbers of intestinal T cells.24 As RA has been shown to regulate expression of intestinal homing molecules such as CCR9 and α4β7 integrin, we first suspected that defective trafficking to the intestine was responsible for the paucity of T cells in the intestines of Hic1ΔT mice; however, we did not observe any defects in the ability of HIC1-deficient T cells to express CCR9 or α4β7. In addition, we observed a significant influx of T cells into intestinal tissues upon induction of inflammation, further suggesting that migration to the intestine is not regulated by expression of HIC1. However, we did observe that the HIC1-deficient T cells present in the intestine at steady state expressed significantly lower levels of the surface molecules CD69 and CD103. These molecules are expressed by tissue-resident cells and are required for retention in tissues. Indeed, similar to our results, CD103-deficient mice have a severe reduction in the number of T cells in the intestine.21 Thus, HIC1 appears to be required for the optimal expression of CD69 and CD103 and retention of T cells in the intestinal microenvironment.
In addition, CD69 and CD103 are characteristic markers of a subset of memory T cells known as tissue resident memory T cells. Tissue resident memory T cells are long-lived quiescent cells that are thought to have derived from effector T cells that have migrated into non-lymphoid tissues. Interestingly, HIC1 has been shown to control fundamental cellular processes such as cell growth and survival.44, 45 HIC1 has been shown to interact with and regulate key transcription factors involved in cell cycle progression and cellular metabolism.37, 46 For example, HIC1 is involved in a regulatory feed back loop with the deacteylase SIRT1,17 which is a key regulator of fatty-acid oxidation.47 Further, it has been demonstrated that fatty-acid metabolism is key to memory T-cell development and survival.48, 49 Thus, it is possible that in addition to directly regulating T-cell retention in tissues, HIC1 may also be required in T cells to promote quiescence through metabolic pathways. Future studies will aim to characterize the role for HIC1 in T-cell quiescence and memory development.
Another observation was the increase in the frequency of IL-17A-producing TH17 cells in the intestine of Hic1ΔT mice. TH17 cells have been shown to have an important role in host defense to extracellular bacteria and fungi.50 However, they have also been described as pathogenic in multiple inflammatory diseases such as psoriasis and rheumatoid arthritis, and targeting IL-17A has proven to be an effective therapy.51, 52, 53 However, the role of IL-17A in inflammatory bowel disease is controversial. Initial studies using the T-cell transfer model of colitis provided the first evidence that IL-23-driven TH17 cells were pathogenic.54 Further, STAT3 was shown to be required to drive both colitis and systemic inflammation not only by modulating TH17-cell differentiation but also by promoting T-cell activation and survival.41 However, targeted therapies against IL-17A in Crohn’s disease have been proven ineffective55, 56 and recent studies have shown that IL-17A is important for maintaining intestinal barrier integrity and has a protective role in regard to the development of colitis.57, 58 Further, it is becoming more apparent that the TH17-cell lineage has a degree of heterogeneity with regards to pathogenicity. For example, TH17 cells differentiated in the presence of TGFβ are less pathogenic and produce higher levels of IL-10, whereas cells differentiated in the presence of IL-23 are more pathogenic and can produce IFN-γ.59, 60 In addition, TH17 cells have a degree of plasticity and fate-mapping studies have shown that “ex-TH17” cells lose their ability to produce IL-17A altogether and exclusively produce IFN-γ under certain conditions.61 As our studies show increased production of IL-17A from TH17 cells and a lack of pathogenicity in multiple mouse models of intestinal inflammation, we hypothesize that in the absence of HIC1, TH17 cells are skewed to a more protective lineage and do not transition into pathogenic cells. Further, it has been shown that STAT3 can inhibit transcription of key genes from other TH-cell lineages62 and therefore may provide TH17 lineage stability in the absence of HIC1. However, the precise molecular mechanism of how HIC1 regulates the pathogenicity of T cells remains to be fully elucidated.
In summary, we have identified the transcription factor HIC1 as an RA-responsive cell-intrinsic regulator of T-cell function in the intestine. Through its interaction with STAT3, HIC1 limits IL-17A production by TH17 cells and is required for the development of intestinal inflammation. Together, these results suggest that HIC1 is an attractive therapeutic target for the treatment of inflammatory diseases of the intestine such as Crohn’s disease and potentially other diseases associated with dysregulated TH17-cell responses.
Methods
Ethics statement. Experiments were approved by the University of British Columbia Animal Care Committee (Protocol number A15-0196) and were in accordance with the Canadian Guidelines for Animal Research.
Mice. The generation of Hic1Citrine mice has been described18 and the generation of Hic1fl/fl mice will be described elsewhere (manuscript in preparation). Cd4-Cre mice were obtained from Taconic (Germantown, NY). Animals were maintained in a specific pathogen-free environment at the Biomedical Research Centre animal facility.
Diet studies. VAD (TD.09838) diet was purchased from Harlan Teklad Diets (Madison, WI). At day 14.5 of gestation, pregnant females were administered the VAD diet and maintained on diet until weaning of litter. Upon weaning, females were returned to standard chow, whereas weanlings were maintained on special diet until use.
Antibodies and flow cytometry. Absolute numbers of cells were determined via hemocytometer or with latex beads for LP samples. Intracellular cytokine staining was performed by stimulating cells with phorbol 12-myristate 13-acetate, ionomycin, and Brefeldin-A (Sigma, St. Louis, MO) for 4 h and fixing/permeabilizing cells using the eBioscience intracellular cytokine buffer kit. All antibody dilutions and cell staining were done with phosphate-buffered saline containing 2% fetal calf serum, 1 mM ethylenediaminetetraacetic acid, and 0.05% sodium azide. Fixable Viability Dye eFluor 506 was purchased from eBioscience (San Diego, CA) to exclude dead cells from analyses. Prior to staining, samples were Fc-blocked with buffer containing anti-CD16/32 (93, eBioscience) and 1% rat serum to prevent non-specific antibody binding. Cells were stained with fluorescent conjugated anti-CD11b (M1/70; in house), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-TCRβ (H57-597), anti-MHCII (I-A/I-E) (M5/114.15.2), anti-CD11c (N418), anti-F4/80 (BM8), anti-IL17a (17B7), anti-FOXP3 (FJK-16s), anti-B220 (RA3-6B2), anti-TCRγδ (eBioGL3), anti-CD45 (30-F11), anti-CD45RB (C363.16A) anti-α4β7 (DATK32), anti-CCR9 (eBioCW-1.2), anti-IFN-γ (XMG1.2), CD25 (PC61.5), IL-13 (eBio13A) purchased from eBioscience, anti-CD103 (M290), anti-CD69 (H1.2F3), anti-CD62L (MEL-14), anti-CD44 (IM7), anti-CD64 (X54.5/7.1.1), anti- phosphorylated STAT3 (pY705) purchased from BD Biosciences (San Jose, CA). Data were acquired on an LSR II flow cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, OR).
RNA isolation and quantitative real-time PCR. Tissues were mechanically homogenized and RNA was extracted using the TRIzol method according to the manufacturer’s instructions (ThermoFisher Scientific, Waltham, MA). cDNA was generated using High Capacity cDNA reverse transcription kits (ThermoFisher Scientific). Quantitative PCR was performed using SYBR FAST (Kapa Biosystems, Wilmington, MA) and SYBR green-optimized primer sets run on an ABI 7900 real-time PCR machine. Cycle threshold (CT) values were normalized relative to beta-actin (Actb) gene expression. The primers used were synthesized de novo:
Hic1:
forward 5′-AACCTGCTAAACCTGGACCAT-3′
reverse 5′-CCACGAGGTCAGGGATCTG-3′
Il17a:
forward 5′-AGCAGCGATCATCCCTCAAAG-3′
reverse 5′-TCACAGAGGGATATCTATCAGGGTC-3′
Ifng:
forward 5′- GGATGCATTCATGAGTATTGCC-3′
reverse 5′-CCTTTTCCGCTTCCTGAGG-3′
Il13:
forward 5′-CCTGGCTCTTGCTTGCCTT-3′
reverse 5′- GGTCTTGTGTGATGTTGCTCA-3′
Foxp3:
forward 5′- CCCAGGAAAGACAGCAACCTT-3′
reverse 5′- TTCTCACAACCAGGCCACTTG-3′
Rorc:
forward 5′- TCCACTACGGGGTTATCACCT-3′
reverse 5′- AGTAGGCCACATTACACTGCT-3′
Socs3:
forward 5′- TGCAAGGGGAATCTTCAAAC-3′
reverse 5′- TGGTTATTTCTTTTGCCAGC-3′
Irf4:
forward 5′- CCGACAGTGGTTGATCGACC-3′
reverse 5′- CCTCACGATTGTAGTCCTGCTT-3′
Ahr:
forward 5′- GCCCTTCCCGCAAGATGTTAT-3′
reverse 5′- GCTGACGCTGAGCCTAAGAAC-3′
Il23r:
forward 5′- AACAACAGCTCGGATTTGGTAT-3′
reverse 5′- ATGACCAGGACATTCAGCAGT-3′
Actb:
forward 5′-GGCTGTATTCCCCTCCATCG-3′
reverse 5′-CCAGTTGGTAACAATGCCATGT-3′.
Cell culture. CD4+ T cells were isolated from spleen and LNs by negative selection using an EasySep Mouse CD4+ T cell isolation kit (StemCell Technologies, Vancouver, BC). In total, 5 × 105 CD4+ cells were cultured for up to 5 days in Dulbecco's Modified Eagle's medium-supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U ml-1 penicillin, 100 μg ml-1 streptomycin, 25 mM HEPES, and 5 × 10-5 2-ME with 1 μg ml-1 plate bound anti-CD3 (145-2C11) and anti-CD28 (37.51). CD4+ T cells were polarized under TH17 cell- (20 ng ml-1 IL-6, 10 ng ml-1 IL-23, TNF-α, IL-1β, 1 ng ml-1 TGF-β1, 10 μg ml-1, anti-IFN-γ and anti-IL-4), TH1 cell- (10 ng ml-1 IL-2, IL-12, and 5 μg ml-1 anti-IL-4), TH2 cell- (10 ng ml-1 IL-2, IL-4, and 5 μg ml-1 anti-IFN-γ) or induced Treg cell- (10 ng ml-1 IL-2 and TGFβ1) promoting conditions. In some cases, cells were plated as above in the presence of 10 nM RA (Sigma-Aldrich).
ELISA. IL-17A production was analyzed from supernatants taken on day 4 of CD4+ T cell in vitro culture using commercially available antibody pairs (eBioscience).
Anti-CD3-induced intestinal inflammation. Mice were administered 30 μg of anti-CD3ɛ antibody (145-2C11) in 400 μl phosphate-buffered saline by intraperitoneal injection. Animals were monitored daily after injection and euthanized at 48 h post injection. At end point, sections of the distal ileum were fixed in 10% buffered formalin, embedded in paraffin, and stained with haematoxylin and eosin. Histological inflammations were blindly scored on a scale of 0 to 4, where 0 represented a normal ileum and 4 represented severe inflammation. Specific aspects such as infiltrating immune cells, crypt length, epithelial erosion, and muscle thickness were taken into account.
T-cell transfer colitis. CD4+ cells were enriched from spleens and peripheral LNs of Hic1fl/fl or Hic1ΔT mice with an EasySep Mouse CD4+ T cell isolation kit (StemCell Technologies) and stained with anti-CD4, anti-CD25, and anti-CD45RB. Naive CD4+CD25–CD45RBhi cells were purified by cell sorting. CD4+CD25–CD45RBhi naive T cells (4 × 105) were injected intraperitoneally into age-and sex-matched Rag1–/– mice, which were monitored for weight loss and killed 6 weeks after initiation of the experiment. At end point, proximal colon was fixed, embedded, and stained with haematoxylin and eosin. Histological inflammation was scored as above.
DSS-induced colitis. Mice were exposed to 3.5% DSS in their drinking water for 7 days before returning to regular drinking water for 1 final day. Mice were monitored for weight loss and killed on day 8. At end point, proximal colon was fixed, embedded, and stained with haematoxylin and eosin. Histological inflammation was scored as above.
Isolation of intraepithelial and LPLs. Peyer’s patches were removed from the small intestine, which was cut open longitudinally, briefly washed with ice-cold phosphate-buffered saline and cut into 1.5 cm pieces. Tissue was incubated in 2 mM ethylenediaminetetraacetic acid phosphate-buffered saline for 15 min at 37 °C and extensively vortexed. Supernatants were collected and pelleted then re-suspended in 30% Percoll solution and centrifuged for 10 min at 1200 rpm. The pellet was collected and used as intraepithelial leukocytes. Remaining tissue was digested with Collagenase/Dispase (Roche) (0.5 mg ml-1) on a shaker at 250 rpm, 37 °C, for 60 min, extensively vortexed and filtered through a 70 μm cell strainer. The flow-through cell suspension was centrifuged at 1500 rpm for 5 min. The cell pellet was re-suspend in 30% Percoll solution and centrifuged for 10 min at 1200 rpm. The pellet was collected and used as LPLs.
Cell lysis, immunoprecipitation, and immunoblotting. Cells were lysed and immunoprecipitation carried out using antibodies against STAT3 (C-20; Santa Cruz, Dallas, TX) and FLAG (M2; Sigma). Immunoblotting was carried out using antibodies against STAT3, HIC1 (H-123; Santa Cruz) and GAPDH (GA1R; in house).
Chromatin immunoprecipitiation. Naive CD4+ T cells were activated and TH17 polarized for 3 days, followed by cross-linking for 8 min with 1% (vol/vol) formaldehyde. Cells were collected, lysed, and sonicated. After being precleared with protein A agarose beads (EMD Millipore, Billerica, MA), cell lysates were immunoprecipitated overnight at 4 °C with anti-STAT3 (C-20, Santa Cruz) or normal rabbit IgG (Cell Signaling, Danvers, MA). After washing and elution, cross-links were reversed for 4 h at 65 °C. Eluted DNA was purified and samples were analyzed by quantitative real time PCR on a 7900 Real-Time PCR system. Primer sets used for analysis are: Il17a promoter forward 5′- CACCTCACACGAGGCACAAG -3′ and reverse 5′-ATGTTTGCGCGTCCTGATC -3′; Il5 promoter forward 5′-AAGTCTAGCTACCGCCAATA-3′ and reverse 5′- AGCAAAGGTGAGTTCAATCT-3′. Each Ct value was normalized to the corresponding input value.
Retroviral transduction. Platinum E cells were transiently transfected using the calcium phosphate method with MigR1 expression plasmids encoding GFP alone or FLAG-HIC1. Viral supernatants were collected after 48 h, supplemented with 8 μg ml-1 polybrene (EMD Millipore) and added to T cells that had been activated under TH17 cell-polarizing conditions for 48 h. T cells (2 × 106) were incubated in 24-well plates with 1 ml viral supernatants. After 24 h, viral supernatant was replaced with conditioned culture medium and cells were cultured under TH17 cell-polarizing conditions for an additional 3 days.
Statistics. Data are presented as mean±s.e.m. Statistical significance was determined by a two-tailed Student’s t-test using GraphPad Prism 5 software. Results were considered statistically significant with P<0.05.
References
Scott, C.L., Aumeunier, A.M. & Mowat, A.M. Intestinal CD103+ dendritic cells: master regulators of tolerance? Trends Immunol. 32, 412–419 (2011).
Smith, P., Smythies, L., Shen, R., Greenwell-Wild, T., Gliozzi, M. & Wahl, S. Intestinal macrophages and response to microbial encroachment. Mucosal immunol. 4, 31–42 (2011).
Bain, C.C. & Mowat, A.M. Macrophages in intestinal homeostasis and inflammation. Immunological Reviews 260, 102–117 (2014).
Littman, D.R. & Rudensky, A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845–858 (2010).
Cheroutre, H., Lambolez, F. & Mucida, D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat. Rev. Immunol. 11, 445–456 (2011).
Suzuki, K., Ha, S., Tsuji, M. & Fagarasan, S. Intestinal IgA synthesis: a primitive form of adaptive immunity that regulates microbial communities in the gut. Semin. Immunol. 19, 127–135 (2007).
Kelly, K.F. & Daniel, J.M. POZ for effect—POZ-ZF transcription factors in cancer and development. Trends Cell Biol. 16, 578–587 (2006).
Lee, S.-U. & Maeda, T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 247, 107–119 (2012).
Allman, D. et al. BCL-6 expression during B-cell activation. Blood 87, 5257–5268 (1996).
Nurieva, R.I. et al. Bcl6 mediates the development of T follicular helper cells. Science 325, 1001–1005 (2009).
Savage, A.K. et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29, 391–403 (2008).
Constantinides, M.G., McDonald, B.D., Verhoef, P.A. & Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397–401 (2014).
Muroi, S. et al. Cascading suppression of transcriptional silencers by ThPOK seals helper T cell fate. Nat. Immunol. 9, 1113–1121 (2008).
Wang, L. et al. Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. Nat. Immunol. 9, 1122–1130 (2008).
Chen, W.Y. et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet. 33, 197–202 (2003).
Wales, M.M. et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1, 570–577 (1995).
Chen, W.Y., Wang, D.H., Yen, R.C., Luo, J., Gu, W. & Baylin, S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437–448 (2005).
Pospichalova, V. et al. Generation of two modified mouse alleles of the Hic1 tumor suppressor gene. Genesis 49, 142–151 (2011).
Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355–360 (2004).
Skon, C.N., Lee, J.-Y., Anderson, K.G., Masopust, D., Hogquist, K.A. & Jameson, S.C. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat. Immunol. 14, 1285–1293 (2013).
Schön, M.P. et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J. Immunol. 162, 6641–6649 (1999).
Brown, C.C. et al. Retinoic acid is essential for Th1 cell lineage stability and prevents transition to a Th17 cell program. Immunity 42, 499–511 (2015).
Hall, J.A. et al. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity 34, 435–447 (2011).
Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C. & Song, S.-Y. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527–538 (2004).
Johansson-Lindbom, B. et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063–1073 (2005).
Hill, J.A. et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 29, 758–770 (2008).
Mucida, D. et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256–260 (2007).
Mucida, D. et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 30, 471–472 (2009) author reply 472–3.
Schambach, F., Schupp, M., Lazar, M.A. & Reiner, S.L. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur. J. Immunol. 37, 2396–2399 (2007).
Esplugues, E. et al. Control of TH17 cells occurs in the small intestine. Nature 475, 514–518 (2011).
Merger, M. et al. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor in T cell induced mucosal damage in the mouse intestine. Gut 51, 155–163 (2002).
Rutz, S. et al. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature 518, 417–421 (2015).
Powrie, F., Leach, M.W., Mauze, S., Caddle, L.B. & Coffman, R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5, 1461–1471 (1993).
Chassaing, B., Aitken, J.D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, Unit 15.25 (2014).
Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy, R.P. & Elson, C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107, 1643–1652 (1994).
Boulay, G. et al. Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins. J. Biol. Chem. 287, 10509–10524 (2012).
Van Rechem, C., Boulay, G., Pinte, S., Stankovic-Valentin, N., Guérardel, C. & Leprince, D. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol. Cell Biol. 30, 4045–4059 (2010).
Hu, B. et al. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Cancer Lett. 376, 387–398 (2016).
Lin, Y.-M., Wang, C.-M., Jeng, J.-C., Leprince, D. & Shih, H.-M. HIC1 interacts with and modulates the activity of STAT3. Cell Cycle 12, 2266–2276 (2013).
Valenta, T., Lukas, J., Doubravska, L., Fafilek, B. & Korinek, V. HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J. 25, 2326–2337 (2006).
Durant, L. et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32, 605–615 (2010).
Kang, S.G., Park, J., Cho, J.Y., Ulrich, B. & Kim, C.H. Complementary roles of retinoic acid and TGF-β1 in coordinated expression of mucosal integrins by T cells. Mucosal Immunol. 4, 66–82 (2011).
Lalevée, S. et al. Genome-wide in silico identification of new conserved and functional retinoic acid receptor response elements (direct repeats separated by 5 bp). J. Biol. Chem. 286, 33322–33334 (2011).
Dehennaut, V., Loison, I., Pinte, S. & Leprince, D. Molecular dissection of the interaction between HIC1 and SIRT1. Biochem. Biophys. Res. Commun. 421, 384–388 (2012).
Rood, B.R. & Leprince, D. Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics. Expert Opin. Ther. Targets 17, 811–827 (2013).
Li, P. et al. Interferon gamma (IFN-γ) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic Acids Res. 40, 1609–1620 (2012).
Gerhart-Hines, Z. et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 26, 1913–1923 (2007).
Pearce, E.L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103–107 (2009).
van der Windt, G.J.W. & Pearce, E.L. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol. Rev. 249, 27–42 (2012).
Annunziato, F., Romagnani, C. & Romagnani, S. The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 135, 626–635 (2015).
Genovese, M.C. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929–939 (2010).
Leonardi, C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190–1199 (2012).
Papp, K.A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181–1189 (2012).
Ahern, P.P. et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33, 279–288 (2010).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
Targan, S.R. et al. Mo2083 a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology 143, e26 (2012).
Lee, J.S. et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43, 727–738 (2015).
Maxwell, J.R. et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity 43, 739–750 (2015).
Lee, Y. et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991–999 (2012).
McGeachy, M.J. et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell–mediated pathology. Nat. Immunol. 8, 1390–1397 (2007).
Hirota, K. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12, 255–263 (2011).
Wan, C.-K. et al. Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. Proc. Natl. Acad. Sci. 112, 9394–9399 (2015).
Acknowledgements
We thank C. Hunter, K. Jacobson, and S. Gerondakis for advice on the manuscript. We thank R. Dhesi, L. Rollins (BRC core), A. Johnson (UBCFlow), M. Williams (UBC AbLab), T. Murakami (BRC Genotyping), I. Barta (BRC Histology), and all members of BRC mouse facility for excellent technical assistance. This work was supported by the Canadian Institutes of Health Research's (CIHR) Canadian Epigenetics, Environment and Health Research Consortium (grant 128090 to C. Zaph) and operating grants (MOP-89773 and MOP-106623 to C. Zaph) and Australian National Health and Medical Research Council (NHMRC) project grants (APP1104433 and APP1104466 to C. Zaph). F. Antignano is the recipient of a CIHR/Canadian Association of Gastroenterology/Crohn’s and Colitis Foundation of Canada postdoctoral fellowship. C. Zaph is a Michael Smith Foundation for Health Research Career Investigator and a veski innovation fellow.
Author Contributions
K.B., F.A., A.C., M.B., S.S. and C.Z. designed and performed the experiments. T.M.U. and V.K. provided assistance and contributed reagents and materials. K.B. and C.Z. wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declared no conflict of interest.
Additional information
SUPPLEMENTARY MATERIAL is linked to the online version of the paper
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Burrows, K., Antignano, F., Bramhall, M. et al. The transcriptional repressor HIC1 regulates intestinal immune homeostasis. Mucosal Immunol 10, 1518–1528 (2017). https://doi.org/10.1038/mi.2017.17
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mi.2017.17